Insights

Xcenda

Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions

Inverted color AmerisourceBergen icon
Xcenda
June 2019

Opening the Gate on Protected Classes: How CMS’ Proposed Rule May Unleash a Wave of Value-Based Decision Making

Inverted color AmerisourceBergen icon
Xcenda
May 2019

HTA Quarterly | Spring 2019

Inverted color AmerisourceBergen icon
Xcenda
May 2019

21st Century Cures Act: Impact on US Stakeholders

Inverted color AmerisourceBergen icon
Xcenda
May 2019

Can Patients Help Influence Drug Development? Where are We with Respect to Patient Input on Early Scientific Advice in North America and Europe?

Inverted color AmerisourceBergen icon
Xcenda
May 2019

Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model

Inverted color AmerisourceBergen icon
Xcenda
May 2019

The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability

Jennifer Snow, MPH
March 2019

Manufacturers

Managing the Growing Expansion of Copay Accumulators

Corey Ford
Corey Ford, MHA
Xcenda
March 2019

Original Report: Impact Analysis of ICER Formulary Implementation in Medicaid

Inverted color AmerisourceBergen icon
Xcenda
March 2019

Assessment of Emerging Therapies for Cystic Fibrosis

Inverted color AmerisourceBergen icon
Xcenda
February 2019

Diabetes and the Growing Investment in Drugs, Devices, and Diagnostics 

Inverted color AmerisourceBergen icon
Xcenda
February 2019

MCDA: Too Much Talk, Too Little Progress?

Inverted color AmerisourceBergen icon
Xcenda
February 2019

HTA Quarterly | Winter 2019

Inverted color AmerisourceBergen icon
Xcenda
February 2019

Manufacturers

Medicare Part B: Do Providers Choose Treatment Based on Payment?

Inverted color AmerisourceBergen icon
Xcenda
January 2019

What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.

Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries

Inverted color AmerisourceBergen icon
Xcenda
December 2018

Valuing CAR-T Therapies: Facing New Challenges, Fulfilling the Potential

Inverted color AmerisourceBergen icon
Xcenda
November 2018

Wearing Your Data: A Global Perspective

Inverted color AmerisourceBergen icon
Xcenda
November 2018

Catalonia: Understanding Market Access Within an Autonomous Region in Spain

Inverted color AmerisourceBergen icon
Xcenda
November 2018

Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments

Inverted color AmerisourceBergen icon
Xcenda
October 2018

Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Japan’s Ongoing Shift From a Traditional Reimbursement Assessment to a Novel Cost-Effectiveness Submission Requirement

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division

Inverted color AmerisourceBergen icon
Xcenda
September 2018

HTA Quarterly | Fall 2018

Inverted color AmerisourceBergen icon
Xcenda
September 2018

HTA Quarterly | Late Summer 2018

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Emerging Trends in PBM Restrictions on Commercial Copay Assistance

Corey Ford
Corey Ford, MHA
Xcenda
August 2018

Manufacturers

How Policy Impacts Patient Support

Ana Stojanovska
August 2018

What role does the changing healthcare coverage landscape play in support program demand and design?

Portugal: A Glimpse into Europe's Future in an Era of Austerity and HTA Reform?

Inverted color AmerisourceBergen icon
Xcenda
July 2018

Connected Health: The Next Healthcare Frontier

Inverted color AmerisourceBergen icon
Xcenda
July 2018

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Ana Stojanovska
June 2018

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Ana Stojanovska
June 2018

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

Top Trends in Health Policy in Canada: Insights from InnomarLive

Inverted color AmerisourceBergen icon
Innomar Strategies
June 2018

The European Medicines Agency to Find a New Home After Brexit

Inverted color AmerisourceBergen icon
Xcenda
June 2018

Are Emerging Value Frameworks a Path to Implementing Value-Based Pricing?

Inverted color AmerisourceBergen icon
Xcenda
June 2018

HTA Quarterly | Summer 2018

Inverted color AmerisourceBergen icon
Xcenda
June 2018

Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries

Inverted color AmerisourceBergen icon
Xcenda
May 2018

Webinar: The Emergence of Copay Accumulator Programs

Corey Ford
Corey Ford, MHA
Xcenda
May 2018

State-Led: The Push for Transparency in Drug Pricing

Inverted color AmerisourceBergen icon
Xcenda
April 2018

Manufacturers

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2018

Insights from managed care executives on the future of coverage and outcomes evaluation.

Manufacturers

Seeing the Value and Transparency of Medicare Part B

Jennifer Snow, MPH
April 2018

HTA Quarterly Spring 2018

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Achieving Market Access Across the Globe for CGTs

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Payer Tactics to Manage Commercial Copay Assistance Gaining Traction

Corey Ford
Corey Ford, MHA
Xcenda
March 2018

Implementing Coverage With Evidence Development

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Recent Trends in Oncology Appraisal Decisions: NICE vs. SMC

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector

Benjamin Parcher, PharmD, MS
Xcenda
February 2018

2018 Trends-Leaning Into the Chaos

Inverted color AmerisourceBergen icon
Xcenda
January 2018

Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity

Inverted color AmerisourceBergen icon
Xcenda
January 2018

Manufacturers

What Do Payers Think About Digital Health Technologies

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2017

How are payers thinking about apps, wearables and other digital health technologies?

HTA Quarterly Late Summer 2017

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Brazil—The Largest Market in Latin America

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine

Inverted color AmerisourceBergen icon
Xcenda
September 2017

HTA Quarterly | Summer 2017

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers

Jennifer Snow, MPH
August 2017

Hearing the Patient Voice: How 4 Countries are Utilizing Patient Input

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Understanding the Columbian Health Care Market

Inverted color AmerisourceBergen icon
Xcenda
August 2017

HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Biosimilar Coding—Could There Be Billions in Hidden Savings?

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Commercializing Cell and Gene Therapies

Inverted color AmerisourceBergen icon
Xcenda
June 2017

Payer Perceptions and Utilization of ICER Value Assessment Framework

Inverted color AmerisourceBergen icon
Xcenda
June 2017

FDAMA 114 and the 21st Century Cures Act

Inverted color AmerisourceBergen icon
Xcenda
May 2017

HTA Quarterly | Spring 2017

Inverted color AmerisourceBergen icon
Xcenda
May 2017

When the Outcome of an Appraisal Is Not NICE: An Overview of the Appeal Process

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Navigating Coverage and Reimbursement for Immunotherapy in Oncology

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Revisiting the Familiar: Time to Re-evaluate the GVD?

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Xcenda Conducts Unique Research on Air Medical Services Costs

Inverted color AmerisourceBergen icon
Xcenda
March 2017

Multiple Myeloma: Rapidly Advancing Therapeutic Landscape

Inverted color AmerisourceBergen icon
Xcenda
January 2017

HTA Quarterly | Winter 2017

Inverted color AmerisourceBergen icon
Xcenda
January 2017

Indication-specific Pricing: What should manufacturers expect in key markets

Inverted color AmerisourceBergen icon
Xcenda
January 2017

HTA Quarterly | Fall 2016

Inverted color AmerisourceBergen icon
Xcenda
October 2016

Singapore: Key Insights Into One of the World’s Most Efficient Healthcare Systems

Inverted color AmerisourceBergen icon
Xcenda
October 2016

Psoriasis and Psoriatic Arthritis: Harnessing the Potential of Targeted Therapies

Inverted color AmerisourceBergen icon
Xcenda
October 2016

Rapid Access in the US, UK, and France

Inverted color AmerisourceBergen icon
Xcenda
October 2016

Analyzing the impact of Medicare Part D for Oncology Patients

Inverted color AmerisourceBergen icon
Xcenda
June 2016

Part B Drug Payment Change: Understanding the Implications for Pharma

Jennifer Snow, MPH
March 2016

Oncology in the Era of Value Frameworks: Perspectives Payers Oncologists Product Planning

Inverted color AmerisourceBergen icon
Xcenda
December 2015